A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40kDa vasculostatin from tumor suppressor BAI1

Oncogene

Volumn 31, Issue 50, 2012, Pages 5144-5152

  Cork, S M ^a   Kaur, B ^a,c   Devi, N S ^a   Cooper, L ^b   Saltz, J H ^b   Sandberg, E M ^a   Kaluz, S ^a,b   Van Meir, E G ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

angiogenesis; brain; cancer; glioma

Indexed keywords

ANGIOGENESIS INHIBITOR; BRAIN SPECIFIC ANGIOGENESIS INHIBITOR; FURIN; G PROTEIN COUPLED RECEPTOR; MATRIX METALLOPROTEINASE 14; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOSTATIN 40;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SECRETION;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; BRAIN NEOPLASMS; CELL LINE, TUMOR; FURIN; GENES, TUMOR SUPPRESSOR; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MATRIX METALLOPROTEINASE 14; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE HYDROLASES; PROPROTEIN CONVERTASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS;

EID: 84871234437     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.1     Document Type: Article

References (46)

1. Kaur B, Brat DJ, Calkins CC, Van Meir EG. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol 2003; 162: 19-27.
2. Nam DH, Park K, Suh YL, Kim JH. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 2004; 11: 863-869.
3. Yoshida Y, Oshika Y, Fukushima Y, Tokunaga T, Hatanaka H, Kijima H et al. Expression of angiostatic factors in colorectal cancer. Int J Oncol 1999; 15: 1221-1225.
4. Fukushima Y, Oshika Y, Tsuchida T, Tokunaga T, Hatanaka H, Kijima H et al. Brainspecific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer. Int J Oncol 1998; 13: 967-970.
5. Hatanaka H, Oshika Y, Abe Y, Yoshida Y, Hashimoto T, Handa A et al. Vascularization is decreased in pulmonary adenocarcinoma expressing brainspecific angiogenesis inhibitor 1 (BAI1). Int J Mol Med 2000; 5: 181-183.
6. Kudo S, Konda R, Obara W, Kudo D, Tani K, Nakamura Y et al. Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma. Oncol Rep 2007; 18: 785-791.
7. Duda DG, Sunamura M, Lozonschi L, Yokoyama T, Yatsuoka T, Motoi F et al. Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis. Br J Cancer 2002; 86: 490-496.
8. Yoon KC, Ahn KY, Lee JH, Chun BJ, Park SW, Seo MS et al. Lipid-mediated delivery of brain-specific angiogenesis inhibitor 1 gene reduces corneal neovascularization in an in vivo rabbit model. Gene Ther 2005; 12: 617-624.
9. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-873.
10. Zhu D, Hunter SB, Vertino PM, Van Meir EG. Overexpression of MBD2 contributes to epigenetic silencing of BAI1 in glioblastoma. Cancer Res 2011; 71: 5859-5870.
11. Nishimori H, Shiratsuchi T, Urano T, Kimura Y, Kiyono K, Tatsumi K et al. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 1997; 15: 2145-2150.
12. Cork SM, Van Meir EG. Emerging roles for the BAI1 protein family in the regulation of phagocytosis, synaptogenesis, neurovasculature, and tumor development. J Mol Med 2011; 89: 743-752.
13. Van Meir EG, Polverini PJ, Chazin VR, Huang H-JS, de Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 1994; 8: 171-176.
14. Zhang X, Lawler J. Thrombospondin-based antiangiogenic therapy. Microvasc Res 2007; 74: 90-99.
15. Gupta K, Gupta P, Wild R, Ramakrishnan S, Hebbel RP. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 1999; 3: 147-158.
16. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997; 138: 707-717.
17. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6: 41-48.
18. de Fraipont F, Nicholson AC, Feige JJ, Van Meir EG. Thrombospondins and tumor angiogenesis. Trends Mol Med 2001; 7: 401-407.
19. Nicholson AC, Malik SB, Logsdon Jr JM, Van Meir EG. Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization. BMC Evol Biol 2005; 5: 11.
20. Park D, Tosello-Trampont AC, Elliott MR, Lu M, Haney LB, Ma Z et al. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 2007; 450: 430-434.
21. Kaur B, Brat DJ, Devi NS, Van Meir EG. Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 2005; 24: 3632-3642.
22. Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Waterman P et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 2010; 18: 285-294.
23. Kaur B, Cork SM, Sandberg EM, Devi NS, Zhang Z, Klenotic PA et al. Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res 2009; 69: 1212-1220.
24. Guedez L, Rivera AM, Salloum R, Miller ML, Diegmueller JJ, Bungay PM et al. Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol 2003; 162: 1431-1439.
25. Takahashi S, Nakagawa T, Kasai K, Banno T, Duguay SJ, Van de Ven WJ et al. A second mutant allele of furin in the processing-incompetent cell line, LoVo. Evidence for involvement of the homo B domain in autocatalytic activation. J Biol Chem 1995; 270: 26565-26569.
26. Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 1996; 393: 101-104.
27. Cao J, Rehemtulla A, Pavlaki M, Kozarekar P, Chiarelli C. Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase. J Biol Chem 2005; 280: 10974-10980.
28. Duckert P, Brunak S, Blom N. Prediction of proprotein convertase cleavage sites. Protein Eng Des Sel 2004; 17: 107-112.
29. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002; 3: 753-766.
30. Fillmore HL, VanMeter TE, Broaddus WC. Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J Neurooncol 2001; 53: 187-202.
31. Hotary KB, Yana I, Sabeh F, Li XY, Holmbeck K, Birkedal-Hansen H et al. Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMPdependent and-independent processes. J Exp Med 2002; 195: 295-308.
32. Itoh Y, Takamura A, Ito N, Maru Y, Sato H, Suenaga N et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. Embo J 2001; 20: 4782-4793.
33. Turk BE, Huang LL, Piro ET, Cantley LC. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol 2001; 19: 661-667.
34. Bjarnadottir TK, Fredriksson R, Hoglund PJ, Gloriam DE, Lagerstrom MC, Schioth HB. The human and mouse repertoire of the adhesion family of G-proteincoupled receptors. Genomics 2004; 84: 23-33.
35. Lin HH, Chang GW, Davies JQ, Stacey M, Harris J, Gordon S. Autocatalytic cleavage of the EMR2 receptor occurs at a conserved G protein-coupled receptor proteolytic site motif. J Biol Chem 2004; 279: 31823-31832.
36. Krasnoperov V, Lu Y, Buryanovsky L, Neubert TA, Ichtchenko K, Petrenko AG. Posttranslational proteolytic processing of the calcium-independent receptor of alpha-latrotoxin (CIRL), a natural chimera of the cell adhesion protein and the G protein-coupled receptor. Role of the G protein-coupled receptor proteolysis site (GPS) motif. J Biol Chem 2002; 277: 46518-46526.
37. Jin Z, Tietjen I, Bu L, Liu-Yesucevitz L, Gaur SK, Walsh CA et al. Disease-associated mutations affect GPR56 protein trafficking and cell surface expression. Hum Mol Genet 2007; 16: 1972-1985.
38. Hsiao CC, Cheng KF, Chen HY, Chou YH, Stacey M, Chang GW et al. Site-specific N-glycosylation regulates the GPS auto-proteolysis of CD97. FEBS Lett 2009; 583: 3285-3290.
39. Klenotic PA, Huang P, Palomo J, Kaur B, Van Meir EG, Vogelbaum MA et al. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol 2010; 176: 2039-2050.
40. Yee KO, Streit M, Hawighorst T, Detmar M, Lawler J. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor-beta. Am J Pathol 2004; 165: 541-552.
41. Belkin AM, Akimov SS, Zaritskaya LS, Ratnikov BI, Deryugina EI, Strongin AY. Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion. J Biol Chem 2001; 276: 18415-18422.
42. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-65.
43. Bassi DE, Mahloogi H, Al-Saleem L, Lopez De Cicco R, Ridge JA, Klein-Szanto AJ. Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 2001; 31: 224-232.
44. Mercapide J, Lopez De Cicco R, Bassi DE, Castresana JS, Thomas G, Klein-Szanto AJ. Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res 2002; 8: 1740-1746.
45. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC et al. Frequent coalterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9: 469-479.
46. Beck-Sickinger AG, Grouzmann E, Hoffmann E, Gaida W, Van Meir EG, Waeber B et al. A novel cyclic analog of neuropeptide Y specific for the Y2 receptor. Eur J Biochem 1992; 206: 957-964.